Abbott Wins FDA Nod for First Dual Glucose-Ketone Monitor
Event summary
- Abbott's Libre Duo 10 Day received FDA authorization on August 25, 2026, becoming the first dual glucose-ketone monitoring system.
- The device integrates continuous glucose monitoring with ketone tracking to prevent diabetic ketoacidosis (DKA).
- Abbott plans U.S. launch later in 2026, with partnerships for automated insulin delivery (AID) systems expected by 2027.
- The system meets new FDA iCGK standards, setting a benchmark for continuous ketone monitoring.
- Libre Duo offers up to 10 days of wear and is designed for diabetes patients aged 2 and older.
The big picture
Abbott's FDA authorization positions it at the forefront of diabetes technology, addressing a critical gap in ketone monitoring. With hospital admissions for DKA rising 55% over the past decade, the Libre Duo 10 Day could become a standard tool in diabetes management. The device's integration with AID systems and broader digital health ecosystems may further solidify Abbott's leadership in biowearables.
What we're watching
- Market Adoption
- How quickly Libre Duo 10 Day gains traction among diabetes patients and healthcare providers.
- Competitive Response
- Whether rivals like Dexcom or Medtronic introduce competing dual-sensor technologies.
- Integration Success
- The pace at which Abbott secures partnerships with AID system manufacturers.